- Home
- NRIX vs SPT Comparison
NRIX vs SPT Comparison
Compare NRIX & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SPT
- Stock Information
- Founded
- NRIX 2009
- SPT 2010
- Country
- NRIX United States
- SPT United States
- Employees
- NRIX N/A
- SPT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SPT Computer Software: Prepackaged Software
- Sector
- NRIX Health Care
- SPT Technology
- Exchange
- NRIX Nasdaq
- SPT Nasdaq
- Market Cap
- NRIX 750.4M
- SPT 687.5M
- IPO Year
- NRIX 2020
- SPT 2019
- Fundamental
- Price
- NRIX $12.78
- SPT $10.01
- Analyst Decision
- NRIX Strong Buy
- SPT Buy
- Analyst Count
- NRIX 14
- SPT 10
- Target Price
- NRIX $26.29
- SPT $27.70
- AVG Volume (30 Days)
- NRIX 1.7M
- SPT 1.3M
- Earning Date
- NRIX 10-09-2025
- SPT 11-05-2025
- Dividend Yield
- NRIX N/A
- SPT N/A
- EPS Growth
- NRIX N/A
- SPT N/A
- EPS
- NRIX N/A
- SPT N/A
- Revenue
- NRIX $83,687,000.00
- SPT $430,795,000.00
- Revenue This Year
- NRIX $58.48
- SPT $13.14
- Revenue Next Year
- NRIX N/A
- SPT $11.85
- P/E Ratio
- NRIX N/A
- SPT N/A
- Revenue Growth
- NRIX 48.32
- SPT 14.79
- 52 Week Low
- NRIX $8.18
- SPT $10.33
- 52 Week High
- NRIX $29.56
- SPT $36.30
- Technical
- Relative Strength Index (RSI)
- NRIX 64.49
- SPT 29.86
- Support Level
- NRIX $11.37
- SPT $10.33
- Resistance Level
- NRIX $12.45
- SPT $11.64
- Average True Range (ATR)
- NRIX 0.75
- SPT 0.47
- MACD
- NRIX 0.20
- SPT 0.08
- Stochastic Oscillator
- NRIX 84.06
- SPT 4.14
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.